A.I. BURNASYAN FMBC CLINICAL BULLETIN

ISSN 2782-6430 (print)

State Research Center −Burnasyan Federal Medical Biophysical
Center of Federal Medical Biological Agency

The journal is published in Russian.
Format – A4.
The periodicity of the journal is 4 times a year.

Issue №2 2025 год

more

A.I. Burnasyan  FMBC clinical bulletin. 2024 № 2

E.Yu. Grishina1,2, E.N. Missyurina1, Jelnova.E.I.1, V.I. Bulygina3, T.A. Astrelina2

Covid-19 Coronavirus Infection in Patients after Hematopoietic Stem Cell
Transplantation: Literature Review and Own Experience

1Moscow City Clinical Hospital 52, Moscow, Russiа

2International Office, State Research Center – Burnasyan Federal Medical Biophysical Center  of Federal Medical Biological Agency, Moscow, Russiа

3Sechenov First Moscow State Medical Univesity Russia, Moscow

Contact person: Astrelina Tatyana Alekseevna: t_astrelina@mail.ru

 

Abstract
The presented literature review presents studies, including our own, on the peculiarities of the course of coronavirus infection in patients after hematopoietic stem cell transplantation (HSCT). It has been shown that patients after HSCT represent an increased risk group for severe COVID-19 and adverse outcomes. The factors that worsen the prognosis of life of patients after HSCT were old age, male gender, uncontrolled/active disease, concomitant diseases, acute course of SARS-CoV-2 COVID19. It is necessary to carry out monitoring, early diagnosis (regular and timely testing for the virus) and the use of effective prevention and treatment protocols in patients after HSCT in a pandemic. Early diagnosis of infection can prevent the spread of the virus, start treatment quickly and take measures to isolate the patient. In the early period after HSCT, patients are at higher risk of developing lower respiratory tract infection, more often need the appointment of antifungal drugs, antibacterial drugs of reserve groups and have greater risks of death from COVID-19. Therapy with genetically engineered biological drugs is not contraindicated in the case of leukopenia and agranulocytosis in this group of patients. As a result of the analysis, there were no differences in the survival rates of patients after autologous and allogeneic HSCT.

Keywords: hematopoietic stem cell transplantation, MERS-CoV-2 coronavirus infection, COVID19, survival, mortality, prognostic factors

For citation: Grishina EYu, Misyurina EN, Zhelnova EI, Bulygina VI, Astrelina TA. Covid-19 Coronavirus Infection in Patients after Hematopoietic Stem Cell Transplantation: Literature Review and Own Experience A.I. Burnasyan Federal Medical Biophysical Center Clinical Bulletin. 2024.2:23-30. (In Russian) DOI: 10.33266/2782-6430-2024-2-23-30

 

REFERENCES

  1. Chan J.F.W., Yuan S., Kok K.H., et al. A Familial Cluster of Pneumonia Associated with the 2019 Novel Coronavirus Indicating Person-to-Person Transmission: a Study of a Family Cluster. Lancet. 2020;395;10223:514. DOI: 10.1016/S0140- 6736(20)30154-9.
  2. Dona D., Torres Canizales J., Benetti E., et al. Pediatric Transplantation in Europe During the COVID-19 Pandemic: Early Impact on Activity and Healthcare. Clin Transplant. 2020;34;10:e14063. DOI: 10.1111/CTR.14063.
  3. Shah G.L., DeWolf S., Lee Y.J. et al. Favorable Outcomes of COVID-19 in Recipients of Hematopoetic Cell Transplantation. J Clin Invest 2020;130;12:6656–6667. DOI: 10.1172/JCI141777.
  4. Sharma A., Bhatt N.S., Martin A.S. et al. Clinical Characteristics and Outcomes of COVID-19 in Haematopoietic Stem-Cell Transplantation Recipients: an Observational Cohort Study. Lancet Haematol. 2021;8;3:тe185–193. DOI: 10.1016/S2352-3026(20)30429-4.
  5. Huang J., Lin H., Wu Y., et al. COVID-19 in Posttransplant Patients – Report of 2 Cases. Am. J. Transplant. 2020;20;7:1879–1881. DOI: 10.1111/AJT.15896.
  6. Matsuda S., Koyasu S. Mechanisms of Action of Cyclosporine. Immunopharmacology. 2000;47;2–3:119–125. DOI: 10.1016/S0162-3109(00)00192-2.
  7. McMurray R.W., Harisdangkul V. Mycophenolate Mofetil: Selective T Cell Inhibition. Am. J. Med. Sci. 2002;323;4:194–196. DOI: 10.1097/00000441- 200204000-00005.
  8. Knight S.R., Morris P.J. Does the Evidence Support the Use of Mycophenolate Mofetil Therapeutic Drug Monitoring in Clinical Practice? A Systematic Review. Transplantation. 2008;85;12:1675–1685. DOI: 10.1097/TP.0B013E3181744199.
  9. Spratt J.S., Hoag M.G. Incidence of Multiple Primary Cancers Per Man-Year of Follow up:20-Year Review from the Ellis Fischel State Cancer Hospital. Ann. Surg. 1966;164;5:775–784. DOI: 10.1097/00000658-196611000-00001.
  10. Oltolini C., Guidetti A., Ripa M., et al. Coronavirus Disease 2019 in Recipient of Allogeneic Hematopoietic Stem Cell Transplantation: Life-Threating Features Within the Early Post-Engraftment Phase. HemaSphere. 2020;4;4:4. DOI: 10.1097/HS9.0000000000000448.].
  11. Dellière S., Dudoignon E., Fodil S., et al. Risk Factors Associated with COVID-19-Associated Pulmonary Aspergillosis in ICU Patients: a French Multicentric Retrospective Cohort. Clin. Microbiol. Infect. 2020;27;5:790.e1–e5. DOI: 10.1016/J.CMI.2020.12.005.].
  12. Passamonti F., Salvini M., Grossi P.A., et al. Clinical Characteristics and Risk Factors Associated with COVID-19 Severity in Patients with Haematological Malignancies in Italy: a Retrospective, Multicentre, Cohort Study. Artic Lancet Haematol. 2020;7:737–82. DOI: 10.1016/S2352-3026(20)30251-9.
  13. Siniaev A.A., Popova M.O., Rogacheva Y.A., et al. Journey of a hematopoietic stem cell transplantation center through COVID-19 Pandemic:One-Year Experience. Cell Ther. Transplant. 2021;10;3-4:30-37. DOI: 10.18620/ctt-1866-8836-2021-10-3-4-30-37.
  14. Daudt L.E., Corso M.C.M., Kerbauy M.N., et al. COVID-19 in HSCT Recipients: a Collaborative Study of the Brazilian Society of Marrow Transplantation (SBTMO). Bone Marrow Transplant. 2022;57;3:453–459. DOI: 10.1038/s41409-021-01561-x.
  15. Миронова Д.А., Васильева В.А., Дроков М.Ю., Чабаева Ю.А., Кузьмина Л.А., Паровичникова Е.Н. Инфекция COVID-19 у больных, перенесших трансплантацию аллогенных гемопоэтических стволовых клеток // Гематология и трансфузиология. 2024. Т.69, № 1. C. 8–19. [Mironova D.A., Vasilyeva V.A., Drokov M.Yu., Chabayeva Yu.A., Kuzmina L.A., Parovichnikova E.N. COVID-19 Infection in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. Gematologiya i Transfuziologiya = Russian Journal of Hematology and Transfusiology. 2024;69;1:8–19 (In Russ.)]. https://doi. org/10.35754/0234-5730-2024-69-1-8-19.
  16. Schmidt-Hieber M., Schwarck S., Stroux A., et al. Immune Reconstitution and Cytomegalovirus Infection after Allogeneic Stem Cell Transplantation: the Important Impact of in Vivo T Cell Depletion. Int. J. Hematol. 2010;91;5:877–885. DOI: 10.1007/S12185-010-0597-6.
  17. Попова Н. Реконституция субпопуляций Т-клеток памяти у больных острыми лейкозами после трансплантации аллогенных гемопоэтических стволовых клеток: Автореф. дис. … канд. мед. наук. М., 2020. [Popova N. Rekonstitutsiya Subpopulyatsiy T-Kletok Pamyati u Bolnykh Ostrymi Leykozami Posle Transplantatsii Allogennykh Gemopoeticheskikh Stvolovykh Kletok = Reconstitution of Subpopulations of Memory T Cells in Patients with Acute Leukemia after Transplantation of Allogeneic Hematopoietic Stem Cells. Extended abstract of candidate’s thesis in Medicine. Moscow Publ., 2020. (In Russ.)].
  18. Синяев А.А., Гриненко А.О., Попова М.О., Рогачева Ю.А., Спиридонова А.А., Власова Ю.Ю., Смирнова А.Г., Морозова Е.В., Лепик К.В., Михайлова Н.Б., Владовская М.Д., Бондаренко С.Н., Моисеев И.С., Кулагин А.Д. Новая коронавирусная инфекция у реципиентов трансплантации гемопоэтических стволовых клеток // Клиническая микробиология и антимикробная химиотерапия. 2022. Т.24, № 3. С. 196-201. [Sinyayev A.A., Grinenko A.O., Popova M.O., Rogacheva Yu.A., Spiridonova A.A., Vlasova Yu.Yu., Smirnova A.G., Morozova E.V., Lepik K.V., Mikhaylova N.B., Vladovskaya M.D., Bondarenko S.N., Moiseyev I.S., Kulagin A.D. COVID-19 Infection in Hematopoietic Stem Cell Transplant Recipients. Klinicheskaya Mikrobiologiya i Antimikrobnaya Himioterapiya = Clinical Microbiology and Antimicrobial Chemotherapy 2022;24;3:196-201 (In Russ.)]. DOI: 10.36488/cmac.2022.3.196-201.
  19. Ljungman P., de la Camara R., Mikulska M., et al. COVID-19 and Stem Cell Transplantation; Results from an EBMT and GETH Multicenter Prospective Survey. Leukemia. 2021;35;10:2885–2894. DOI: 10.1038/S41375-021-01302-5.
  20. Pagano L., Salmanton-García J., Marchesi F., Busca A., Corradini P., Hoenigl M., et.al. EPICOVIDEHA Working Group. COVID-19 Infection in Adult Patients with Hematological Malignancies: a European Hematology Association Survey (EPICOVIDEHA). J. Hematol. Oncol. 2021;14;1:168. DOI: 10.1186/s13045-021-01177-0.
  21. Moiseev I.S., Dotsenko A.A., Smirnova A.G., Vlasova Y.Y., Morozova E.V., Bondarenko S.N., et al. Long-Term Goals in the Treatment of Chronic Graft-Versus-Host Disease after Matched Allogeneic Hematopoietic Stem Cell Transplantation. Cell Ther. Transplant. 2020;9;4:29-36. DOI: 10.18620/ ctt-1866-8836-2020-9-4-29-36.
  22. Judith Schaffrath, Christina Brummer, Daniel Wolff, Udo Holtick, Nicolaus Kröger, et. al. High Mortality of COVID-19 Early after Allogeneic Stem Cell Transplantation: a Retrospective Multicenter Analysis on Behalf of the German Cooperative Transplant Study Group. Transplantation and Cellular Therapy. 2022;28;6:337.e1-337.e10 DOI: 10.1016/j.jtct.2022.03.010.
  23. Aditi Sharma, Abhinav Deol, Vijendra Singh Mortality in COVID-19 Hospitalizations with Underlying Hematologic Malignancies in the United States Hematol. Oncol. 2023;41;4:781-783. DOI: 10.1002/hon.3173.
  24. Firas El Chaer, Jeffery J. Auletta, Roy F. How I Treat and Prevent COVID-19 in Patients with; Hematologic Malignancies and Recipients of Cellular Therapies. Chemaly. Blood. 2022;140;7:673–684.
  25. Ulrike Scharmann, Frank Herbstreit, Nina Kristin Steckel, Jutta Dedy 4, Jan Buer, Peter-Michael Rath, Hedda Luise Verhasselt. Prevalence of COVID-19 Associated Mucormycosis in a German Tertiary Care Hospital. J. Fungi (Basel). 2022;8;3:307. DOI: 10.3390/jof8030307.
  26. Cordonnier C., Einarsdottir S., Cesaro S., et al. Vaccination of Haemopoietic Stem Cell Transplant Recipients: Guidelines of the 2017 European Conference on Infections in Leukaemia (ECIL 7). Lancet Infect. Dis. 2019;19;6:e200–12. DOI: 10.1016/S1473-3099(18)30600-5.].
  27. NCCN National Comprehensive Cancer Network. Prevention and treatment of Cancer-Related Infections. URL: https://www.nccn.org/ guidelines/guidelines-detail?category=3&id=1457. 02.03.2022.
  28. Khawaja F., Chemaly R.F., Dadwal S., et al. ASH-ASTCT COVID-19 Vaccination for HCT and CAR T Cell Recipients. URL: https://www.hematology.org/covid-19/ash-astct-covid-19-vaccination-for-hct-and-car-t-cell-recipients.
  29. COVID-19 vaccines. URL: https://www.ebmt.org/sites/default/fi les/2022-01/COVID %20vaccines %20version %208.3 %20-%202022-01-03.pdf.
  30. Ведение пациентов онкогематологического профиля в период пандемии COVID-19 / Под ред. Поддубной. И.В. М.: Экон-Информ, 2022. 140 с. [Vedeniye Patsiyentov Onkogematologicheskogo Profilya v Period Pandemii COVID-19 = Management of Hematological Oncology Patients During the COVID-19 Pandemic. Ed. Poddubnaya I.V. Moscow, Ekon-Inform Publ., 2022. 140 p. (In Russ.)]. ISBN 978-5-907427-70-9.
  31. Logunov D.Y., Dolzhikova I. V., Shcheblyakov D. V., et al. Safety and Effi Cacy of an rAd26 and rAd5 Vector-Based Heterologous Prime-Boost COVID-19 Vaccine: an Interim Analysis of a Randomised Controlled Phase 3 Trial in Russia. Lancet. 2021;397;10275:671. DOI: 10.1016/S0140-6736(21)00234-8.
  32. Гаврилина О.А., Васильева А.Н. Вакцинация от COVID-19 гематологических больных:обзор клинических рекомендаций. Гематология и трансфузиология. 2021. Т.66, № 3. C. 458–470. [Gavrilina O.A., Vasilyeva A.N. Vaccination Against COVID-19 for Hematologic Patients: A Review of Clinical Guidelines. Gematologiya i Transfuziologiya = Russian Journal of Hematology and Transfusiology. 2021;66;3:458–470. (In Russ.)]. DOI: 10.35754/0234-5730-2021-66-3-458-470.
  33. Piñana J.L., López-Corral L., Martino R., et al. SARS-CoV-2-Reactive Antibody Detection after SARS-CoV-2 Vaccination in Hematopoietic Stem Cell Transplant Recipients: Prospective Survey from the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group. Am. J. Hematol. 2022;97;1:30–42. DOI: 10.1002/AJH.26385.
  34. Ali H., Ngo D., Aribi A., et al. Safety and Tolerability of SARS-CoV2 Emergency-Use Authorized Vaccines for Allogeneic Hematopoietic Stem Cell Transplant Recipients. Transplant Cell Ther. 2021;27;11:938.e1–e6. DOI: 10.1016/J. JTCT.2021.07.008.
  35. Bergman P., Blennow O., Hansson L., et al. Safety and Effi Cacy of the mRNA BNT162b2 Vaccine Against SARS-CoV-2 in fi ve Groups of Immunocompromised Patients and Healthy Controls in a Prospective Open-Label Clinical Trial. EBioMedicine. 2021;74:103705. DOI: 10.1016/J.EBIOM.2021.103705.
  36. Joshua A. Hill, Michael J. Martens, Jo-Anne H. Young, Kavita Bhavsar, Jianqun Kou , Min Chen, et al. SARS-CoV-2 Vaccination in the First Year after Allogeneic Hematopoietic Cell Transplant: a Prospective, Multicentre, Observational Study E. Clinical. Medicine. 2023;59:101983. DOI: 10.1016/j.eclinm.2023.101983.
  37. Pan H., Peto R., Henao-Restrepo A.M., Preziosi M.P., Sathiyamoorthy V., et.al. Repurposed Antiviral Drugs for Covid-19 – Interim WHO Solidarity Trial Results. WHO Solidarity Trial Consortium. N. Engl. J. Med. 2021;384;6:497-511. DOI: 10.1056/NEJMoa2023184.
  38. Гришина Е.Ю., Мисюрина Е. Н., Желнова Е. И. и др. Течение коронавирусной инфекции после трансплантации стволовых клеток крови. Онкогематология. 2023. Т.18, № 4. С. 91–95. [Grishina E.Yu., Misyurina E. N., Zhelnova E. I., et al. Coronavirus infection after blood stem cell transplantation. Onkogematologiya = Oncohematology. 2023;18;4:91–95. (In Russ.)]. DOI: https: //doi.org/10.17650/1818‑8346‑2023-18‑4.
  39. Giammarco S., Sica S., Metafuni E., et al. Impact of COVID 19 Pandemic on Hematopoietic Stem Cell Transplantation Activities: Report from a Single Center. Transfus. Apher. Sci. 2023;62;4:103708. DOI: 10.1016/j.transci.2023.103708.

Conflict of interest. The authors declare no conflict of interest.
Financing. The study had no sponsorship. 
Contribution. Article was prepared with equal participation of the authors.
Article received: 25.04.2024. Accepted for publication: 16.05.2024

© 2025 Scientific journal - "Clinical Bulletin of the FMBС im. A.I. Burnasyan"
Scroll to Top